Abstract
Objective: to evaluate the impact of therapy with chondroitin sulfate (CS) and glucosamine (GA) on the clinical manifestations of low back pain (LBP). Subjects and methods. A multicenter open-label observational prospective study was conducted in 22 cities of Russia (46 centers) to investigate the efficacy of a combination of CS and GA in the outpatient treatment of nonspecific LBP. A total of 9761 patients were enrolled in the study that was completed by 8546 patients. Therapeutic efficiency was evaluated from changes in pain intensity during movement and at rest, by using the visual analogue scale. The Oswestry disability index, an global physician and patient assessment of therapeutic efficiency, and a daily need for nonsteroidal anti-inflammatory drugs (NSAIDs) were taken into account as additional criteria for efficiency evaluation. Results and discussion. The multicenter open-label observational study established the efficacy of a combination of CS and GA in treating nonspecific LBP: relief in pain during movement and at rest, functional improvement, and a reduction in the daily need for NSAIDs. The patients and physicians highly assessed therapeutic efficiency. The combination of CS and GA was also noted to be well tolerated. The findings may suggest that this combination may be a promising tool to treat LBP and gives proof to the expediency of its use in randomized placebo-controlled studies.
Highlights
Цель исследования – оценить влияние терапии хондроитина сульфатом (ХС) и глюкозамина (ГА) гидрохлоридом на клинические проявления боли в нижней части спины (БНС)
A multicenter open-label observational prospective study was conducted in 22 cities of Russia (46 centers) to investigate the efficacy of a combination of chondroitin sulfate (CS) and GA in the outpatient treatment of nonspecific low back pain (LBP)
A total of 9761 patients were enrolled in the study that was completed by 8546 patients
Summary
В условиях многоцентрового открытого наблюдательного исследования установлена эффективность комбинации ХС и ГА при лечении неспецифической БНС: отмечено уменьшение боли при движении и в покое, улучшение функционального статуса, снижение суточной потребности в НПВП. The multicenter open-label observational study established the efficacy of a combination of CS and GA in treating nonspecific LBP: relief in pain during movement and at rest, functional improvement, and a reduction in the daily need for NSAIDs. The patients and physicians highly assessed therapeutic efficiency. Практически во всех рекомендациях [3], созданных для клинической практики, указывается, что при обращении любого больного с БНС необходимо исключить серьезную патологию, признаки которой обозначаются как «красные флаги» (пожилой возраст, травма, необъяснимая лихорадка или похудание, не проходящая в покое боль, подозрение на онкологическое заболевание).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
